** Arcus Biosciences shares RCUS.N drop 4% to $12.57 premarket
** Arcus's 13.6 mln stock offering priced at $11 each, a 16% discount to last close
** Co plans to use gross proceeds of ~$150 mln to develop its experimental kidney cancer drug and for other purposes
** Goldman Sachs, Leerink Partners and Evercore ISI were joint book-runners
** Prior to offering, RCUS had 91.5 mln outstanding shares for $1.20 bln market cap, per LSEG data
(Reporting by Arasu Kannagi Basil in Bengaluru)
((ArasuKannagi.Basil@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.